Desmoid Tumors Market Size to hit US$ 3.05Billion by 2033 | Top Companies Growth - Immunome Inc., Apollomics, Inc., Iterion Therapeutics, Inc

global desmoid tumors market size reached US$1.88Billion in 2024 from US$1.79Billionin 2023 and is expected to reach US$ 3.05Billion by 2033, growing at a CAGR of 5.6%during the forecast period 2025-2033.

Get a Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/desmoid-tumors-market?kb

Latest M&A and Industry Activity

✅ SpringWorks Therapeutics, a Merck unit, is a leading player with its approved drug OGSIVEO (nirogacestat), the first therapy for progressing desmoid tumors in the US and Europe.​

✅ Ayala Pharmaceuticals completed patient enrollment ahead of schedule in the Phase 3 RINGSIDE study evaluating AL102, a gamma secretase inhibitor for desmoid tumors, and recently agreed on a business transaction with Immunome for related assets.​

✅ Companies focusing on targeted therapies and rare tumors continue strategic partnerships to expand pipeline potential and facilitate commercialization.

Key Players:

Spring Works Therapeutics, Inc., Immunome Inc., Apollomics, Inc., Iterion Therapeutics, Inc., and Parabilis Medicines

Key Development:

➠ In August 2025, Merck announced that the European Commission approved OGSIVEO (nirogacestat) as the first oral therapy in the EU for adults with progressing desmoid tumors requiring systemic treatment. This approval was granted to Spring Works Therapeutics, a Merck healthcare company.

➠ In October 2025, Parabilis Medicines revealed groundbreaking clinical data at the ESMO Congress showing its investigational FOG-001 therapy successfully targeted the previously "undruggable" β-catenin:TCF pathway in desmoid tumors during ongoing Phase 1/2 trials.

➠ In February 2024, Immunome, Inc. acquired AL102 and AL101 from Ayala Pharmaceuticals in a deal valued at up to $87.5 million, strengthening its oncology pipeline with promising γ-secretase inhibitors.

➠ Other key pipeline players include Iterion Therapeutics' tegavivint, disrupting Wnt signaling, and next-gen inhibitors like Parabilis' FOG-001 and Cellestia's CB-103 targeting Wnt/β-catenin and Notch pathways. These therapies aim to broaden treatment options, improve tolerability, and help patients resistant to existing drugs.

Growth Forecast Projected:

The Global Desmoid Tumors Market is anticipated to rise at a considerable rate during the forecast period, between 2025 and 2032. In 2024, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Research Process:

Both primary and secondary data sources have been used in the global Desmoid Tumors Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Buy Now & Get 30% OFF - (Grab 50% OFF on 2+ reports) @: https://www.datamintelligence.com/buy-now-page?report=desmoid-tumors-market?kb

Key Segments:

By Tumor Type: (Abdominal Wall Desmoid Tumors, Intra-Abdominal Desmoid Tumors, and Extra-Abdominal Desmoid Tumors)

By Treatment Type: (Targeted Therapy, Radiation Therapy, Chemotherapy, Hormone Therapy, Cryoablation, and Others)

By End-User: (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, and Others)

Regional Analysis for Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Approved Drugs and Product Launches

✦ Nirogacestat (OGSIVEO) is FDA and EMA approved, demonstrating significant improvement in progression-free survival (PFS), objective response rate (ORR), and quality of life in clinical trials, with efficacy maintained over four years of continuous treatment.​

✦ AL102 from Ayala Pharmaceuticals is in Phase 3 trials targeting systemic desmoid tumor treatment with potential best-in-class gamma secretase inhibition.​

✦ Other promising investigational agents include Tegavivint (BC2059), Vactosertib, E7386, and tyrosine kinase inhibitors like imatinib and pazopanib.

Get Customization in the report as per your requirements: https://datamintelligence.com/customize/desmoid-tumors-market?kb

FAQ's

Q1: What is the current size of the Desmoid Tumors Market?

A: The Desmoid Tumors Market stood at US$1.88Billion in 2024 and is set to experience remarkable growth, reaching US$ 3.05Billion by 2033

Q2: How fast is the Desmoid Tumors Market growing?

A: The Market is on an impressive growth trajectory, expected to expand at a CAGR of 5.6% from 2025 to 2032

Get 2-Day Free Trial + 50% OFF DataM Subscription@: https://www.datamintelligence.com/reports-subscription?kb

Clinical Trials and Research Highlights

⇥ The Phase 3 DeFi trial of nirogacestat showed a 71% reduction in the risk of disease progression in patients with progressing desmoid tumors, with sustained tumor size reduction and symptom relief.​​

⇥ Several ongoing trials explore combination therapies, immune modulation, and novel delivery methods aiming to improve efficacy and reduce side effects.​

⇥ Research focuses on mutation-driven disease subsets, especially CTNNB1 mutations, which constitute the majority of cases, to develop precision therapies.​

Market and Patient Impact

1. The desmoid tumor treatment market is expected to experience significant growth through 2034, driven by rising disease awareness, improved diagnostics, and the introduction of targeted therapies.​

2. Patient-centric outcomes including pain management, mobility improvement, and psychological well-being are increasingly emphasized in clinical development.

3. Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.